News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
Here are highlights of our activities in the first half of 2020 as we work towards building a world of mental wellbeing for everyone.
Announcement of our successful $80m Series B investment round completion.
Letter from our co-founders explaining how we have changed our work to keep people safe during this pandemic.
Article discussing the granted psilocybin patent. Featuring a comment from co-founder George Goldsmith on what this means for COMPASS Pathways.
Here are highlights of our activities in the second half of 2019 that we hope will move us closer to our goal of improving mental health care for as many as possible.
An overview of the healthy volunteer study at Kings College London, where COMPASS Pathways COMP360 (psilocybin) was found to be well tolerated.
Here are highlights of our activities in the first half of 2019 that we hope will move us closer to our goal of improving mental health care for as many as possible.
As 2018 draws to a close, we reflect on another busy year and share our highlights of the last few months with you.
Article written for the MAPS Bulletin Winter 2018. By Ekaterina Malievskaia, MD, MSc
COMPASS Pathways, a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health ...
This is the second of regular newsletters from COMPASS, highlighting recent and forthcoming events and developments that are relevant to us, our partners and healthcare system stakeholders.
The holiday season is approaching, and as we begin dreaming of festive treats and spending the holidays cocooned in thick duvets with a cup of hot chocolate in hand, I would like to reflect on our journey this past year and share a few 2017 highlights.